Key result
Small extracellular vesicles offer novel therapeutic options and serve as novel biomarkers for the diagnosis and treatment of urological tumors.
Why the study?
Urological tumors are difficult to diagnose and treat due to high metastatic rates, drug resistance, and low sensitivity of liquid biopsies, highlighting the need to explore small extracellular vesicles as novel biomarkers and therapeutic options.
Small extracellular vesicles show potential as novel biomarkers and therapeutic options, including vaccines and drug carriers, for urological tumors.
sEVs may offer biomarkers and therapies for urological tumors; hypothesis-generating and requires prospective validation before practice change.
Extracellular vesicles (EVs) are important mediators of communication between tumor cells and normal cells. These vesicles are rich in a variety of contents such as RNA, DNA, and proteins, and can be involved in angiogenesis, epithelial-mesenchymal transition, the formation of pre-metastatic ecological niches, and the regulation of the tumor microenvironment. Small extracellular vesicles (sEVs) are a type of EVs. Currently, the main treatments for urological tumors are surgery, radiotherapy, and targeted therapy. However, urological tumors are difficult to diagnose and treat due to their high metastatic rate, tendency to develop drug resistance, and the low sensitivity of liquid biopsies. Numerous studies have shown that sEVs offer novel therapeutic options for tumor treatment, such as tumor vaccines and tumor drug carriers. sEVs have attracted a great deal of attention owing to their contribution to in intercellular communication, and as novel biomarkers, and role in the treatment of urological tumors. This article reviews the research and applications of sEVs in the diagnosis and treatment of urological tumors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a review in Urological tumors. Small extracellular vesicles (sEVs) was evaluated. Small extracellular vesicles offer novel therapeutic options and serve as novel biomarkers for the diagnosis and treatment of urological tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: